CA3158293C - Lipid composition - Google Patents

Lipid composition Download PDF

Info

Publication number
CA3158293C
CA3158293C CA3158293A CA3158293A CA3158293C CA 3158293 C CA3158293 C CA 3158293C CA 3158293 A CA3158293 A CA 3158293A CA 3158293 A CA3158293 A CA 3158293A CA 3158293 C CA3158293 C CA 3158293C
Authority
CA
Canada
Prior art keywords
group
ethyl
carbon atoms
lipid
lipid composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3158293A
Other languages
English (en)
French (fr)
Other versions
CA3158293A1 (en
Inventor
Takahiro Sekiguchi
Taisuke Endo
Shun Kaneumi
Masaki Noro
Shintaro TANABE
Masahiko Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CA3158293A1 publication Critical patent/CA3158293A1/en
Application granted granted Critical
Publication of CA3158293C publication Critical patent/CA3158293C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
CA3158293A 2019-11-15 2020-11-13 Lipid composition Active CA3158293C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019207118 2019-11-15
JP2019-207118 2019-11-15
PCT/JP2020/042513 WO2021095876A1 (ja) 2019-11-15 2020-11-13 脂質組成物

Publications (2)

Publication Number Publication Date
CA3158293A1 CA3158293A1 (en) 2021-05-20
CA3158293C true CA3158293C (en) 2024-06-25

Family

ID=75912395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3158293A Active CA3158293C (en) 2019-11-15 2020-11-13 Lipid composition

Country Status (11)

Country Link
US (1) US20220273817A1 (https=)
EP (2) EP4059505B1 (https=)
JP (2) JP7389134B2 (https=)
KR (4) KR20250171478A (https=)
CN (2) CN117417265B (https=)
CA (1) CA3158293C (https=)
DK (1) DK4328309T3 (https=)
ES (1) ES3036322T3 (https=)
FI (1) FI4328309T3 (https=)
PL (1) PL4328309T3 (https=)
WO (1) WO2021095876A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102591743B1 (ko) 2018-06-08 2023-10-19 후지필름 가부시키가이샤 화합물 또는 그 염 및 지질 입자
WO2020246581A1 (ja) 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
CN117279888A (zh) * 2021-04-28 2023-12-22 富士胶片株式会社 化合物或其盐、脂质颗粒及药物组合物
CN114149337B (zh) * 2021-07-07 2022-04-29 天津键凯科技有限公司 一种用于核酸递送的新型可电离脂质及其lnp组合物
CN120420422A (zh) * 2022-01-30 2025-08-05 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
CN118891051A (zh) 2022-03-15 2024-11-01 富士胶片株式会社 脂质组合物
CN118984831A (zh) 2022-03-15 2024-11-19 富士胶片株式会社 化合物及脂质组合物
WO2023178425A1 (en) * 2022-03-23 2023-09-28 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles
WO2024014430A1 (ja) 2022-07-11 2024-01-18 富士フイルム株式会社 アミノ脂質又はその塩の製造中間体としての化合物、及びそれを用いたアミノ脂質化合物の製造方法
AU2023316579A1 (en) 2022-07-29 2025-02-13 Fujifilm Corporation COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
JP2025537180A (ja) * 2022-11-03 2025-11-14 シャンハイ サーコード バイオメッド カンパニー,リミティド 脂質化合物、脂質ナノ粒子、及び医薬組成物
WO2024158042A1 (ja) * 2023-01-27 2024-08-02 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
AU2024234895A1 (en) 2023-03-13 2025-09-18 Fujifilm Corporation Compound or salt thereof, lipid composition, pharmaceutical composition, and delivery carrier
WO2025070702A1 (ja) * 2023-09-27 2025-04-03 富士フイルム株式会社 抗体の産生方法、および抗体の産生方法において使用するための脂質組成物
WO2025143232A1 (ja) * 2023-12-28 2025-07-03 富士フイルム株式会社 免疫細胞への核酸送達剤、および免疫細胞に核酸を送達する方法
WO2025192731A1 (ja) * 2024-03-15 2025-09-18 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
WO2026004829A1 (ja) * 2024-06-24 2026-01-02 富士フイルム株式会社 脂質ナノ粒子の製造方法
WO2026004828A1 (ja) * 2024-06-24 2026-01-02 富士フイルム株式会社 脂質ナノ粒子の製造方法
CN120535478A (zh) * 2025-01-23 2025-08-26 上海环码生物医药有限公司 脂质化合物、脂质纳米颗粒和药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
JP5288254B2 (ja) 2008-10-17 2013-09-11 株式会社ニコン レンズ系
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP2013245107A (ja) 2012-05-29 2013-12-09 Kuma Lift Gijutsu Kenkyusho:Kk 椅子式階段昇降装置
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
US10426737B2 (en) * 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
HUE060907T2 (hu) * 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
JP6637988B2 (ja) 2014-11-18 2020-01-29 アークトゥルス セラピューティクス, インコーポレイテッド Rna送達のためのイオン化可能カチオン性脂質
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
AU2017356699B2 (en) * 2016-11-08 2021-11-11 Ramot At Tel-Aviv University Ltd. Cationic lipids for nucleic acid delivery and preparation thereof
KR102591743B1 (ko) * 2018-06-08 2023-10-19 후지필름 가부시키가이샤 화합물 또는 그 염 및 지질 입자
WO2020246581A1 (ja) * 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
JP7518909B2 (ja) * 2020-09-14 2024-07-18 富士フイルム株式会社 脂質組成物

Also Published As

Publication number Publication date
CN114728016A (zh) 2022-07-08
ES3036322T3 (en) 2025-09-17
FI4328309T3 (fi) 2025-09-09
JP7389134B2 (ja) 2023-11-29
DK4328309T3 (da) 2025-08-18
US20220273817A1 (en) 2022-09-01
KR20220082885A (ko) 2022-06-17
JPWO2021095876A1 (https=) 2021-05-20
PL4328309T3 (pl) 2025-11-17
EP4059505A4 (en) 2023-01-11
WO2021095876A1 (ja) 2021-05-20
CN117417265A (zh) 2024-01-19
KR20250171478A (ko) 2025-12-08
EP4328309A2 (en) 2024-02-28
EP4059505B1 (en) 2024-02-21
EP4328309B1 (en) 2025-07-02
KR20250057122A (ko) 2025-04-28
EP4059505A1 (en) 2022-09-21
KR20240090627A (ko) 2024-06-21
CN114728016B (zh) 2024-10-29
CN117417265B (zh) 2026-02-10
EP4328309A3 (en) 2024-09-25
JP7566078B2 (ja) 2024-10-11
CA3158293A1 (en) 2021-05-20
JP2023116626A (ja) 2023-08-22

Similar Documents

Publication Publication Date Title
CA3158293C (en) Lipid composition
EP3981435B1 (en) Lipid composition
CA3102985C (en) Compound or salt thereof and lipid particles
WO2024158042A1 (ja) 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
CN114828830A (zh) 药物组合物及处置剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W00-W00-W604 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: GRANT DOWNLOADED

Effective date: 20240702

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241031

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241031

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250930